spacer
home > news > detailed info
INDUSTRY NEWS AND PRESS RELEASES

Thermo Fisher Scientific Adds Patterned Microchip-based Technology to Liquid Chromatography Portfolio

Thermo Fisher Scientific

Extends capabilities in column performance for biopharma and proteomics researchers


PHILADELPHIA – ASMS 2021 – (November 1, 2021)
– Thermo Fisher Scientific, the world leader in serving science, today announced its acquisition of Belgium-based PharmaFluidics, the developer of the μPAC range of micro-chip-based chromatography columns.

The μPAC portfolio of columns enhance liquid chromatography (LC) performance in biomarker, proteomics and drug research and development applications, helping biotechnology and pharmaceutical companies uncover new insights and advance scientific discovery. Through an innovative approach, separation performance and sensitivity are improved with the μPAC chromatography columns, allowing for the identification of substantially more compounds in complex biological samples. The μPAC portfolio acquisition complements Thermo Fisher’s existing chromatography solutions to deliver extended analytical capabilities to researchers.

“LC is a key analytical technique across numerous applications, and its accuracy, reproducibility and robustness is critical to the delivery of meaningful results,” said Kent Davidson, vice president and general manager, high performance chromatography solutions, chromatography and mass spectrometry, Thermo Fisher Scientific. “Columns are an essential part of these workflows, and the next-generation μPAC columns push this element to a new level through innovative pillar array technology, improving the quality of data.”

The μPAC columns deliver excellent separation and sensitivity to achieve greater identifications from samples with a large dynamic range, ultimately enhancing the solutions available for pharmaceutical laboratories to help meet changing needs in medical research.
phone 800-556-2323
web corporate.thermofisher.com/en/home.html
email 168 Third Avenue Waltham, MA 02451
 
Print this page
Send to a friend
   
spacer
News and Press Releases

Recursion Announces Transformational Collaboration with Roche and Genentech in Neuroscience and Oncology, Advancing Novel Medicines to Patients Using Machine Learning and High Content Screening Methods at Scale to Map Complex Biology

The deal, worth several billion dollars, is a future-looking model of technology-enabled target and drug discovery
More info >>


White Papers

Migration safe pharmaceutical labels improve patient safety

UPM Raflatac

Labels play an invaluable role on pharmaceutical packages. Pharmaceutical companies should only use labels that meet low-leachability and extraction requirements. Labels that are not migration safe, e.g. create leachable chemical compounds, may fail testing and result in significant launch delays or costly recalls. This white paper presents how pharmaceutical companies can ensure that the final label constructions achieve their business, regulatory and patient safety goals.
More info >>

 
©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement